Q-omics provides the consensus-scored RPL7AP4 profile across patient tissues and cancer cell-line models. RPL7AP4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL7AP4 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, RPL7AP4 RNA expression shows 10,029 significant gene co-expression associations, with the highest sampling consensus in READ. Together, these results highlight ACC, COAD, and READ as cancer lineages where RPL7AP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL7AP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL7AP4 survival associations across molecular data types. RPL7AP4 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL7AP4 RNA expression–survival associations across cancer types. High RPL7AP4 expression shows unfavorable associations in ACC, KIRP, STAD and ESCA, but favorable associations in UCS and UCEC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL7AP4 RNA expression.
This table summarizes RPL7AP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL7AP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL7AP4 shows lower tumor expression in PAAD and higher tumor expression in COAD, THCA, READ, PRAD and LIHC. The COAD box plot shows higher RPL7AP4 RNA expression in tumor versus normal tissue (log2 FC = +1.166, t-test p < 0.001).
This table shows molecular features associated with RPL7AP4 in patient tissues and cancer cell lines. In patient samples, RPL7AP4 shows the broadest associations at the RNA and protein expression levels, with READ recurring as the lineage with the largest associated feature set.
